Supernus Pharma (SUPN) Misses Q4 EPS by 6c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.27, $0.06 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $174.16 million versus the consensus estimate of $150.24 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• FuelCell Energy (FCEL) call put ratio 1 call to 1 put into quarter results
• Can-Am to provide $150,000 and vehicles to Farm Rescue over three years